APA (7th ed.) Citation

Vikelis, M., Rikos, D., Argyriou, A. A., Soldatos, P., Tsironis, C., Giakoumakis, E., . . . Dermitzakis, E. V. (2026). Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group. Neurology International, 18(4), 67. https://doi.org/10.3390/neurolint18040067

Chicago Style (17th ed.) Citation

Vikelis, Michail, et al. "Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group." Neurology International 18, no. 4 (2026): 67. https://doi.org/10.3390/neurolint18040067.

MLA (9th ed.) Citation

Vikelis, Michail, et al. "Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group." Neurology International, vol. 18, no. 4, 2026, p. 67, https://doi.org/10.3390/neurolint18040067.